Document Detail

Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?
MedLine Citation:
PMID:  24564001     Owner:  NLM     Status:  In-Process    
Multiple trials over the past two decades testing omega-3 polyunsaturated fatty acids (PUFAs), containing eicosapentaenoic acid (EPA) and or docosahexaenoic acid (DHA), have shown substantial benefits for reducing major coronary heart disease (CHD) events, all-cause mortality, cardiovascular (CV) death, sudden cardiac death (SCD), and stroke. However, recent trials testing omega-3s have generally failed to confirm these benefits. While increased fish and fish oil intake among the general population, increased use of optimal medical therapy (including statins, aspirin, and modern antihypertensive medications) probably make it more challenging for fish oil supplementation to show additional benefits, there might be further explanations in the formulation, dosage, and comparator used in these recent omega-3 trials.
James J DiNicolantonio; Pascal Meier; James H O'Keefe
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Missouri medicine     Volume:  110     ISSN:  0026-6620     ISO Abbreviation:  Mo Med     Publication Date:    2013 Nov-Dec
Date Detail:
Created Date:  2014-02-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400744     Medline TA:  Mo Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  495-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The current state of ICD-10 & preparing for it.
Next Document:  Obesity: the 'huge' problem in cardiovascular diseases.